Literature DB >> 33778680

Gadoxetate-enhanced Abbreviated MRI for Hepatocellular Carcinoma Surveillance: Preliminary Experience.

Ryan L Brunsing1, Dennis H Chen1, Alexandra Schlein1, Tanya Wolfson1, Anthony Gamst1, Adrija Mamidipalli1, Naik Vietti Violi1, Robert M Marks1, Bachir Taouli1, Rohit Loomba1, Yuko Kono1, Claude B Sirlin1.   

Abstract

Purpose: To describe a single-center preliminary experience with gadoxetate disodium-enhanced abbreviated MRI for hepatocellular carcinoma (HCC) screening and surveillance in patients with cirrhosis or chronic hepatitis B virus (cHBV). Materials and
Methods: This was a retrospective study of consecutive patients aged 18 years and older with cirrhosis or cHBV who underwent at least one gadoxetate-enhanced abbreviated MRI examination for HCC surveillance from 2014 through 2016. Examinations were interpreted prospectively by one of six abdominal radiologists for clinical care. Clinical, imaging, and other data were extracted from electronic medical records. Diagnostic adequacy was assessed in all patients. Diagnostic accuracy was assessed in the subset of patients who could be classified as having HCC or not having HCC on the basis of a composite reference standard.
Results: In this study, 330 patients (93% with cirrhosis; 45% women; mean age, 59 years) underwent gadoxetate-enhanced abbreviated MRI. In the 330 patients, 311 (94.2%) baseline gadoxetate-enhanced abbreviated MRI examinations were diagnostically adequate. Of 141 (43%) of the 330 patients, 91.4% (129 of 141) could be classified as not having HCC and 8.6% (12 of 141) could be classified as having HCC. Baseline gadoxetate-enhanced abbreviated MRI had 0.92 sensitivity (95% confidence interval [CI]: 0.62, 1.00) and 0.91 specificity (95% CI: 0.84, 0.95) for detection of HCC. Of the 330 patients who underwent baseline gadoxetate-enhanced abbreviated MRI, 187 (57%) were lost to follow-up.
Conclusion: Gadoxetate-enhanced abbreviated MRI is feasible clinically, has a high diagnostic adequacy rate, and, on the basis of our preliminary experience, accurately depicts HCC in high-risk patients. Strategies to enhance follow-up compliance are needed.© RSNA, 2019Keywords: Abdomen/GI, Cirrhosis, Liver, MR-Imaging, Oncology, ScreeningSupplemental material is available for this article. 2019 by the Radiological Society of North America, Inc.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 33778680      PMCID: PMC7983773          DOI: 10.1148/rycan.2019190010

Source DB:  PubMed          Journal:  Radiol Imaging Cancer        ISSN: 2638-616X


  40 in total

1.  EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma.

Authors: 
Journal:  Eur J Cancer       Date:  2012-03       Impact factor: 9.162

Review 2.  Diffusion-weighted MR imaging of the liver.

Authors:  Bachir Taouli; Dow-Mu Koh
Journal:  Radiology       Date:  2010-01       Impact factor: 11.105

Review 3.  Asia-Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update.

Authors:  Masao Omata; Ann-Lii Cheng; Norihiro Kokudo; Masatoshi Kudo; Jeong Min Lee; Jidong Jia; Ryosuke Tateishi; Kwang-Hyub Han; Yoghesh K Chawla; Shuichiro Shiina; Wasim Jafri; Diana Alcantara Payawal; Takamasa Ohki; Sadahisa Ogasawara; Pei-Jer Chen; Cosmas Rinaldi A Lesmana; Laurentius A Lesmana; Rino A Gani; Shuntaro Obi; A Kadir Dokmeci; Shiv Kumar Sarin
Journal:  Hepatol Int       Date:  2017-06-15       Impact factor: 6.047

4.  AASLD guidelines for the treatment of hepatocellular carcinoma.

Authors:  Julie K Heimbach; Laura M Kulik; Richard S Finn; Claude B Sirlin; Michael M Abecassis; Lewis R Roberts; Andrew X Zhu; M Hassan Murad; Jorge A Marrero
Journal:  Hepatology       Date:  2018-01       Impact factor: 17.425

Review 5.  2017 Version of LI-RADS for CT and MR Imaging: An Update.

Authors:  Khaled M Elsayes; Jonathan C Hooker; Michelle M Agrons; Ania Z Kielar; An Tang; Kathryn J Fowler; Victoria Chernyak; Mustafa R Bashir; Yuko Kono; Richard K Do; Donald G Mitchell; Aya Kamaya; Elizabeth M Hecht; Claude B Sirlin
Journal:  Radiographics       Date:  2017 Nov-Dec       Impact factor: 5.333

Review 6.  Global epidemiology of hepatocellular carcinoma: an emphasis on demographic and regional variability.

Authors:  Katherine A McGlynn; Jessica L Petrick; W Thomas London
Journal:  Clin Liver Dis       Date:  2015-02-26       Impact factor: 6.126

7.  Meta-analysis: surveillance with ultrasound for early-stage hepatocellular carcinoma in patients with cirrhosis.

Authors:  A Singal; M L Volk; A Waljee; R Salgia; P Higgins; M A M Rogers; J A Marrero
Journal:  Aliment Pharmacol Ther       Date:  2009-04-08       Impact factor: 8.171

Review 8.  Burden of liver disease in Europe: Epidemiology and analysis of risk factors to identify prevention policies.

Authors:  Laura Pimpin; Helena Cortez-Pinto; Francesco Negro; Emily Corbould; Jeffrey V Lazarus; Laura Webber; Nick Sheron
Journal:  J Hepatol       Date:  2018-05-17       Impact factor: 25.083

9.  MRI With Liver-Specific Contrast for Surveillance of Patients With Cirrhosis at High Risk of Hepatocellular Carcinoma.

Authors:  So Yeon Kim; Jihyun An; Young-Suk Lim; Seungbong Han; Ji-Young Lee; Jae Ho Byun; Hyung Jin Won; So Jung Lee; Han Chu Lee; Yung Sang Lee
Journal:  JAMA Oncol       Date:  2017-04-01       Impact factor: 31.777

10.  Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis.

Authors:  V Mazzaferro; E Regalia; R Doci; S Andreola; A Pulvirenti; F Bozzetti; F Montalto; M Ammatuna; A Morabito; L Gennari
Journal:  N Engl J Med       Date:  1996-03-14       Impact factor: 176.079

View more
  9 in total

Review 1.  Abbreviated Magnetic Resonance Imaging for HCC Surveillance.

Authors:  Naik Vietti Violi; Kathryn J Fowler; Claude B Sirlin; Bachir Taouli
Journal:  Clin Liver Dis (Hoboken)       Date:  2021-04-13

2.  Inter-reader agreement of abbreviated magnetic resonance imaging for hepatocellular carcinoma detection: a systematic review and meta-analysis.

Authors:  Dong Hwan Kim; Sang Hyun Choi; Ji Sung Lee; Joon-Il Choi
Journal:  Abdom Radiol (NY)       Date:  2021-10-11

Review 3.  Magnetic resonance imaging for the diagnosis of hepatocellular carcinoma in adults with chronic liver disease.

Authors:  Tin Nadarevic; Agostino Colli; Vanja Giljaca; Mirella Fraquelli; Giovanni Casazza; Cristina Manzotti; Davor Štimac; Damir Miletic
Journal:  Cochrane Database Syst Rev       Date:  2022-05-06

Review 4.  Current and Emerging Tools for Hepatocellular Carcinoma Surveillance.

Authors:  Nia Adeniji; Renumathy Dhanasekaran
Journal:  Hepatol Commun       Date:  2021-09-17

Review 5.  Current Landscape and Future Perspectives of Abbreviated MRI for Hepatocellular Carcinoma Surveillance.

Authors:  Hyo Jung Park; Nieun Seo; So Yeon Kim
Journal:  Korean J Radiol       Date:  2022-04-13       Impact factor: 7.109

Review 6.  [Recent Updates of Abbreviated MRI for Hepatocellular Carcinoma Screening].

Authors:  Jeong Woo Kim; Chang Hee Lee
Journal:  Taehan Yongsang Uihakhoe Chi       Date:  2021-03-31

Review 7.  Abbreviated MR Protocols for Chronic Liver Disease and Liver Cancer.

Authors:  Guillermo Carbonell; Bachir Taouli
Journal:  Magn Reson Imaging Clin N Am       Date:  2021-08       Impact factor: 1.376

Review 8.  Imaging diagnosis of hepatocellular carcinoma: Future directions with special emphasis on hepatobiliary magnetic resonance imaging and contrast-enhanced ultrasound.

Authors:  Junghoan Park; Jeong Min Lee; Tae-Hyung Kim; Jeong Hee Yoon
Journal:  Clin Mol Hepatol       Date:  2021-12-27

9.  Abbreviated MRI Protocol for the Assessment of Ablated Area in HCC Patients.

Authors:  Vincenza Granata; Roberta Grassi; Roberta Fusco; Sergio Venanzio Setola; Andrea Belli; Mauro Piccirillo; Silvia Pradella; Marzia Giordano; Salvatore Cappabianca; Luca Brunese; Roberto Grassi; Antonella Petrillo; Francesco Izzo
Journal:  Int J Environ Res Public Health       Date:  2021-03-30       Impact factor: 3.390

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.